Abstract
Kidney diseases are a major source of morbidity and mortality in humans. In developed countries, mortality owing to chronic kidney disease (CKD) terminating in end-stage renal failure is comparable with that associated with cancer. A full understanding of the mechanisms implicated in the progression of CKD is needed to achieve its prevention and to delay the need for support strategies based on dialysis and transplantation. Renal fibrosis is the unifying feature of progressive renal alterations. In this review, we discuss the current status of possible mechanisms, tools and targets in CKD. Pathophysiological compound identification, biomarker discovery and accurate selection of clinical validation criteria appear to be three key elements needed to develop a successful innovative pharmaceutical approach to treating kidney diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 244-259 |
| Number of pages | 16 |
| Journal | Drug Discovery Today |
| Volume | 16 |
| Issue number | 5-6 |
| DOIs | |
| Publication status | Published - Mar 2011 |
Fingerprint
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
Cite this
The kidney as a target organ in pharmaceutical research. / Prunotto, Marco; Gabbiani, Giulio; Pomposiello, Silvia; Ghiggeri, Gianmarco; Moll, Solange.
In: Drug Discovery Today, Vol. 16, No. 5-6, 03.2011, p. 244-259.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The kidney as a target organ in pharmaceutical research
AU - Prunotto, Marco
AU - Gabbiani, Giulio
AU - Pomposiello, Silvia
AU - Ghiggeri, Gianmarco
AU - Moll, Solange
PY - 2011/3
Y1 - 2011/3
N2 - Kidney diseases are a major source of morbidity and mortality in humans. In developed countries, mortality owing to chronic kidney disease (CKD) terminating in end-stage renal failure is comparable with that associated with cancer. A full understanding of the mechanisms implicated in the progression of CKD is needed to achieve its prevention and to delay the need for support strategies based on dialysis and transplantation. Renal fibrosis is the unifying feature of progressive renal alterations. In this review, we discuss the current status of possible mechanisms, tools and targets in CKD. Pathophysiological compound identification, biomarker discovery and accurate selection of clinical validation criteria appear to be three key elements needed to develop a successful innovative pharmaceutical approach to treating kidney diseases.
AB - Kidney diseases are a major source of morbidity and mortality in humans. In developed countries, mortality owing to chronic kidney disease (CKD) terminating in end-stage renal failure is comparable with that associated with cancer. A full understanding of the mechanisms implicated in the progression of CKD is needed to achieve its prevention and to delay the need for support strategies based on dialysis and transplantation. Renal fibrosis is the unifying feature of progressive renal alterations. In this review, we discuss the current status of possible mechanisms, tools and targets in CKD. Pathophysiological compound identification, biomarker discovery and accurate selection of clinical validation criteria appear to be three key elements needed to develop a successful innovative pharmaceutical approach to treating kidney diseases.
UR - http://www.scopus.com/inward/record.url?scp=79952451067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952451067&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2010.11.011
DO - 10.1016/j.drudis.2010.11.011
M3 - Article
C2 - 21129499
AN - SCOPUS:79952451067
VL - 16
SP - 244
EP - 259
JO - Drug Discovery Today
JF - Drug Discovery Today
SN - 1359-6446
IS - 5-6
ER -